caa a22 4500 445343796 CHVBK 20180317142822.0 cr unu---uuuuu 170323e20110901xx s 000 0 eng 10.1007/s00406-010-0177-z doi (NATIONALLICENCE)springer-10.1007/s00406-010-0177-z Obesity and coronary risk in patients treated with second-generation antipsychotics [Elektronische Daten] [Christoph Correll, John Kane, Peter Manu] Weight gain leading to obesity is a frequent adverse effect of treatment with atypical antipsychotics. However, the degree of its independent contribution to the risk of coronary heart disease events in patients treated with these drugs has not been elucidated. The aim of this study is to determine whether obesity is an independent risk factor for the 10-year risk of coronary heart disease events in psychiatric patients treated with atypical antipsychotics. We used the Framingham method, which is based on age, gender, blood pressure, smoking, and plasma levels of total and high-density lipoprotein cholesterol, to estimate the 10-year risk of coronary heart disease events in patients treated with second-generation antipsychotics who were obese (N=44; mean age 38.1years, 54.5% men) or normal weight (N=83; mean age 39.9years, 47.0% men). Excluded were patients with metabolic syndrome and those taking antihypertensive, hypoglycemic, and lipid-lowering drugs. The 10-year risk of coronary artery disease events was very low and virtually identical in the obese and normal weight patients (2.3±3.5 vs. 2.6±4.6, P=0.68), despite excess of 12 BMI units (P<0.0001) and 15.7cm waist circumference (P<0.0001) in the obese. The risk was similar in obese and normal weight men (3.8±5.9 vs. 2.8±3.4, P=0.45) and women (1.7±3.7 vs. 1.5±2.5, P=0.83). The validity of the 10-year prediction for risk of coronary heart disease events in the mentally ill based on the Framingham score system requires prospective confirmation. Obesity does not appear to be an independent predictor for the 10-year risk of coronary heart disease events in patients without metabolic syndrome treated with second-generation antipsychotics. Springer-Verlag, 2010 Antipsychotics nationallicence Obesity nationallicence Normal weight nationallicence Metabolic syndrome nationallicence Coronary heart disease events nationallicence Risk nationallicence Correll Christoph The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, 75-59 263rd Street, 11004, Glen Oaks, NY, USA aut Kane John The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, 75-59 263rd Street, 11004, Glen Oaks, NY, USA aut Manu Peter The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, 75-59 263rd Street, 11004, Glen Oaks, NY, USA aut European Archives of Psychiatry and Clinical Neuroscience Springer-Verlag 261/6(2011-09-01), 417-423 0940-1334 261:6<417 2011 261 406 https://doi.org/10.1007/s00406-010-0177-z text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00406-010-0177-z text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Correll Christoph The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, 75-59 263rd Street, 11004, Glen Oaks, NY, USA aut NATIONALLICENCE 700 1- Kane John The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, 75-59 263rd Street, 11004, Glen Oaks, NY, USA aut NATIONALLICENCE 700 1- Manu Peter The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, 75-59 263rd Street, 11004, Glen Oaks, NY, USA aut NATIONALLICENCE 773 0- European Archives of Psychiatry and Clinical Neuroscience Springer-Verlag 261/6(2011-09-01), 417-423 0940-1334 261:6<417 2011 261 406 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer